Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumors

被引：0
|
作者：
Mamdani, Hirva [1 ]
Jalal, Shadia I. [2 ]
机构：
[1] Wayne State Univ, Karmanos Canc Inst, 4100 John R, Detroit, MI 48201 USA
[2] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
TRK; ENTRECTINIB; INHIBITOR; ONCOGENE; ROS1;
D O I：
10.21037/atm.2019.06.41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 27 条
  • [1] Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors
    Bokemeyer, Carsten
    Vassal, Gilles
    Italiano, Antoine
    De la Cuesta, Esther
    Hiemeyer, Florian
    Fellous, Marc
    Marian, Marisca
    JCO PRECISION ONCOLOGY, 2021, 5 : 1458 - 1465
  • [2] Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis
    Lemelle, Lauriane
    Guillemot, Delphine
    Hermann, Anne-Laure
    Gauthier, Arnaud
    Carton, Matthieu
    Corradini, Nadege
    Rome, Angelique
    Berlanga, Pablo
    Jourdain, Anne
    Cardine, Aude Marie
    Jannier, Sarah
    Boutroux, Helene
    Defachelles, Anne Sophie
    Aerts, Isabelle
    Geoerger, Birgit
    Karanian, Marie
    Doz, Francois
    Brisse, Herve J.
    Schleiermacher, Gudrun
    Delattre, Olivier
    Pierron, Gaelle
    Orbach, Daniel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (08) : 865 - 874
  • [3] Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers
    Farago, Anna F.
    Demetri, George D.
    FUTURE ONCOLOGY, 2020, 16 (09) : 417 - 425
  • [4] Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review
    Kubota, Yuta
    Kawano, Masanori
    Iwasaki, Tatsuya
    Itonaga, Ichiro
    Kaku, Nobuhiro
    Ozaki, Toshifumi
    Tanaka, Kazuhiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025, : 313 - 326
  • [5] Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors
    Naito, Yoichi
    Mishima, Saori
    Akagi, Kiwamu
    Hayashi, Naomi
    Hirasawa, Akira
    Hishiki, Tomoro
    Igarashi, Ataru
    Ikeda, Masafumi
    Kadowaki, Shigenori
    Kajiyama, Hiroaki
    Kato, Motohiro
    Kenmotsu, Hirotsugu
    Kodera, Yasuhiro
    Komine, Keigo
    Koyama, Takafumi
    Maeda, Osamu
    Miyachi, Mitsuru
    Nishihara, Hiroshi
    Nishiyama, Hiroyuki
    Ohga, Shouichi
    Okamoto, Wataru
    Oki, Eiji
    Ono, Shigeru
    Sanada, Masashi
    Sekine, Ikuo
    Takano, Tadao
    Tao, Kayoko
    Terashima, Keita
    Tsuchihara, Katsuya
    Yatabe, Yasushi
    Yoshino, Takayuki
    Baba, Eishi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (07) : 827 - 840
  • [6] Tropomyosin receptor kinase inhibitors in the management of sarcomas
    Wilding, Christopher P.
    Loong, Herbert H.
    Huang, Paul H.
    Jones, Robin L.
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (04) : 307 - 313
  • [7] Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
    Liu, Dazhi
    Offin, Michael
    Harnicar, Stephen
    Li, Bob T.
    Drilon, Alexander
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1247 - 1252
  • [8] The First Reported Case of Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Thymoma Treated Successfully With Entrectinib
    Salame, Hassan
    Mckey, Remy
    Ballout, Mohamad
    Saad, Wajih
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (12)
  • [9] Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors
    Rosen, Ezra Y.
    Schram, Alison M.
    Young, Robert J.
    Schreyer, Mark W.
    Hechtman, Jaclyn F.
    Shu, Catherine A.
    Ku, Nora C.
    Hyman, David M.
    Drilon, Alexander
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 5
  • [10] Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
    Laetsch, Theodore W.
    Hong, David S.
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4974 - 4982
123